Press Releases


Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

OCEANSIDE, Calif., June 18, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.

“Having Dr. Veltmeyer head up our future “Right To Try Cancer Clinic”, as well as all other clinical programs underway is a dream come true for TSOI,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “In his role as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, where he currently provides senior leadership to over 200 physicians, Dr. Veltmeyer has developed skills that few ever do, allowing him to bring a wealth of experience in management and medicine to bear on our programs. He is one of the most compassionate doctors I have ever known and he will be an amazing Chief Medical Officer to oversee our future clinic where we plan to treat the most critically ill among us, end-stage cancer patients,” added Mr. Dixon.

“The future of medicine is unfolding right before our eyes at a very rapid pace. Cellular immunotherapies, such as the Company’s StemVacs platform allow for reprogramming of the immune system to selectively attack the cancer stem cell, which is believed to be the root of tumor formation,” said Dr. James Veltmeyer. “Having worked with the team at TSOI since joining their Scientific Advisory Board, I have been impressed at the Company’s pragmatic approach towards hyper-accelerated therapeutics development. I look forward to my more involved role in leading clinical translation of the Company’s discoveries from Bench to Bedside.”

“There are very few people I know who can transition seamlessly from business to medicine, to basic research,” said Thomas Ichim, Ph.D., Director of TSOI. “I have worked closely with Dr. Veltmeyer both at TSOI, and as well on his Congressional Campaign. Dr. Veltmeyer is a naturally born leader that cares #1 about patients. I look forward to working alongside Dr. Veltmeyer in transforming the future of medicine,” added Dr. Ichim.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is and e-commerce at

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


Therapeutic Solutions International, Inc.